It is common to hear people complain that the U.S. Food & Drug Administration (FDA) takes too long to approve new cancer therapies or that new drugs are brought to market much sooner in Europe than they are in America. A new and independent assessment of the facts actually suggests quite the opposite. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: approval, biological, drug, EMEA, FDA | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site
